Clinical Trials Directory

Trials / Completed

CompletedNCT04696679

Quality of Life of Very Preterm Children With Dysexecutive Disorders at Elementary School Age During the Confinement-deconfinement Period of Covid-19 Pandemic

Status
Completed
Phase
Study type
Observational
Enrollment
170 (actual)
Sponsor
Assistance Publique Hopitaux De Marseille · Academic / Other
Sex
All
Age
7 Years – 9 Years
Healthy volunteers

Summary

Since March 2020, a new HCoV, SARS-Cov2, originating in China, has been spreading around the world. As of 13 may 2020, almost 4.2 million cases of infections and 292 000 died were reported worldwide (140 000 infection cases and 27 000 died in France). Human coronaviruses (HCoV) usually cause common upper respiratory tract infections in children and sometimes exacerbate lung and asthma diseases. To minimize the risk of contamination of SARS-Cov2 (Covid-19), the French government has put in place directives that modified the daily lives of students, teachers and families. The societal change imposed by the state of health emergency with a confinement and deconfinement period could strongly impact the quality of life of very preterm children with dysexecutive disorders. These children are a population vulnerable to changes, especially during the pivotal period of elementary school. The executive dysfunctions disrupt children's learning and schooling, as well as their social adaptation, compromising their personal development and therefore, their quality of life.

Conditions

Interventions

TypeNameDescription
OTHERPatient Quality of life assessmentOther: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
OTHERControl group Quality of life assessmentOther: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)

Timeline

Start date
2020-06-19
Primary completion
2020-11-30
Completion
2020-12-31
First posted
2021-01-06
Last updated
2021-01-29

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04696679. Inclusion in this directory is not an endorsement.